Given the important role of the PI3K/Akt/mTOR and Raf/Mek/ERK pathways in pituitary tumor pathogenesis, a number of agents targeting these pathways have been investigated in the treatment of pituitary adenomas; however, most evidence of activity comes from preclinical studies. Here, PIK3CA is linked to pituitary gland adenoma.